Objective To observe the effects and safety of Apatinib mesylate in the treatment of advanced pri-mary liver cancer. Methods Sixty patients with advanced primary liver cancer treated in the Department of Oncology in our hospital between January 2014 and December 2015 were selected as the study subjects. By random number table method, the subjects were divided into the observation group and control group, with 30 cases in each group. Patients in the observation group were treated with oral administration of Apatinib mesylate, while patients in the control group were treated with placebo and the best supportive therapy. The clinical remission rate, survival time and the incidence of adverse reactions were compared between the two groups. Results The clinical remission rate in observation group was significantly higher than that in control group (60.0% vs 33.3%, P<0.05). The survival time of observation group was significantly longer than that of control group, (7.2 ± 1.6) months vs (4.4 ± 1.3) months, P<0.05. The total incidence rates of adverse reactions and grade 3 and 4 adverse reactions in the observation group (86.7%, 30.0%) were higher than those in the control group (70.0%, 20.0%), but with no statistically significant difference (P>0.05). Conclusion The ap-plication of Apatinib mesylate in patients with advanced primary liver cancer is conductive to enhancing the clinical effi-cacy and prolonging the survival time of patients, with high safety. It is worthy of clinical promotion and application.%目的 观察甲磺酸阿帕替尼治疗晚期原发性肝癌的疗效及安全性.方法 选择我院肿瘤科2014年1月至2015年12月收治的原发性肝癌患者60例作为研究对象,按随机数表法分为观察组和对照组,每组30例.观察组患者口服甲磺酸阿帕替尼治疗,对照组应用安慰剂及最佳支持治疗,比较两组患者的临床缓解率、生存期及不良反应发生率.结果 观察组患者的临床缓解率为60.0%,高于对照组患者的33.3%,差异有统计学意义(P<0.05);观察组患者的生存期为(7.2±1.6)个月,长于对照组的(4.4±1.3)个月,差异有统计学意义(P<0.05);观察组患者的不良反应总发生率为86.7%,其中3、4级不良反应总发生率为30.0%,对照组患者的不良反应总发生率为70.0%,其中3、4级不良反应总发生率为20.0%,观察组患者的不良反应发生率略高于对照组,但差异均无统计学意义(P>0.05).结论 晚期原发性肝癌患者应用甲磺酸阿帕替尼有利于强化临床疗效,可延长患者生存期,且安全性高,值得临床推广应用.
展开▼
